chronic kidney disease
Conditions
Interventions
Experimental group (roxadustat):No
Control group (recombinant human erythropoietin):No
Sponsors
The Second Affiliated Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: (1) Regular administration of roxadustat or Recombinant human erythropoietin> for 3 months; (2)HB<100g/L (3) Stage 5 chronic kidney disease combined with peritoneal dialysis or hemodialysis.
Exclusion criteria
Exclusion criteria: (1) Patients with gastrointestinal bleeding and blood transfusion during medication; (2) Vitamin B12 or folate deficiency patients or other blood system diseases that cause anemia; (3) use of immunosuppressants; (4) patients with rHuEPO combined with roxadustat; (5) Incomplete clinical data; (6) Patients with rHuEPO combined with roxadustat.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| haemoglobin;red blood cells;Hematocrit;Serum iron;Transferrin saturation;ferritin;C-reactiveprotein;hypersensitive C-reactive protein;cholesterol;Triglycerides;low-density lipoprotein; | — |
Secondary
| Measure | Time frame |
|---|---|
| calcium;phosphorus;magnesium;intact parathyroid hormone;albumin; | — |
Countries
China
Contacts
Public ContactTianbiao Zhou
the Second Affiliated Hospital of Shantou University Medical College
Outcome results
None listed